FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137602317> ?p ?o ?g. }

• W2137602317 endingPage "3830" @default.
• W2137602317 startingPage "3824" @default.
• W2137602317 abstract "Purpose Patients with stage IV non–small-cell lung cancer (NSCLC) who progress through first-line therapy have poor progression-free survival (PFS) and overall survival (OS), most commonly failing in original sites of gross disease. Cytoreduction with stereotactic body radiation therapy (SBRT) may help systemic agents delay relapse. Patients and Methods Patients in our single arm phase II study had stage IV NSCLC with no more than six sites of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and concurrent erlotinib until disease progression. After erlotinib commencement, SBRT with equipotent fractionation was delivered to all sites of disease. PFS, OS, and other end points were evaluated. Results Twenty-four patients (13 men and 11 women) with a median age of 67 years (range, 56-86 years) were enrolled with median follow-up of 11.6 months. All patients had progressed through platinum-based chemotherapy. A total of 52 sites were treated with 16 of 24 patients receiving SBRT to more than one site. Lung parenchyma was most often irradiated. Median PFS was 14.7 months, and median OS was 20.4 months. Most patients progressed in new distant sites with only three of 47 measurable lesions recurring within the SBRT field. Two grade 3 toxicities were radiation related. Zero of 13 patients tested were positive for an EGFR mutation. Conclusion Use of SBRT with erlotinib for unselected patients with stage IV NSCLC as a second- or subsequent line therapy resulted in dramatic changes in patterns of failure, was well tolerated, and resulted in high PFS and OS, substantially greater than historical values for patients who only received systemic agents." @default.
• W2137602317 created "2016-06-24" @default.
• W2137602317 creator A5012323508 @default.
• W2137602317 creator A5024523208 @default.
• W2137602317 creator A5025135477 @default.
• W2137602317 creator A5026905234 @default.
• W2137602317 creator A5029754474 @default.
• W2137602317 creator A5034705456 @default.
• W2137602317 creator A5052966036 @default.
• W2137602317 creator A5055537555 @default.
• W2137602317 creator A5066993165 @default.
• W2137602317 creator A5068359755 @default.
• W2137602317 creator A5071670695 @default.
• W2137602317 creator A5072938690 @default.
• W2137602317 creator A5082517668 @default.
• W2137602317 creator A5089791635 @default.
• W2137602317 creator A5091812069 @default.
• W2137602317 date "2014-12-01" @default.
• W2137602317 modified "2023-09-30" @default.
• W2137602317 title "Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer" @default.
• W2137602317 cites W1215470407 @default.
• W2137602317 cites W1528207664 @default.
• W2137602317 cites W1949705494 @default.
• W2137602317 cites W1978794238 @default.
• W2137602317 cites W1978831940 @default.
• W2137602317 cites W2003251918 @default.
• W2137602317 cites W2023445800 @default.
• W2137602317 cites W2024501410 @default.
• W2137602317 cites W2025837153 @default.
• W2137602317 cites W2029082419 @default.
• W2137602317 cites W2030227571 @default.
• W2137602317 cites W2052354574 @default.
• W2137602317 cites W2057316742 @default.
• W2137602317 cites W2059812828 @default.
• W2137602317 cites W2061383517 @default.
• W2137602317 cites W2070681106 @default.
• W2137602317 cites W2073881958 @default.
• W2137602317 cites W2084089297 @default.
• W2137602317 cites W2084584970 @default.
• W2137602317 cites W2108215699 @default.
• W2137602317 cites W2115646671 @default.
• W2137602317 cites W2126427337 @default.
• W2137602317 cites W2131110909 @default.
• W2137602317 cites W2133203437 @default.
• W2137602317 cites W2135274380 @default.
• W2137602317 cites W2138297714 @default.
• W2137602317 cites W2139483106 @default.
• W2137602317 cites W2144518271 @default.
• W2137602317 cites W2150893131 @default.
• W2137602317 cites W2160166879 @default.
• W2137602317 cites W2166459387 @default.
• W2137602317 cites W2167270572 @default.
• W2137602317 cites W2169961966 @default.
• W2137602317 cites W2406483134 @default.
• W2137602317 cites W4231096603 @default.
• W2137602317 cites W4239112513 @default.
• W2137602317 cites W4240340450 @default.
• W2137602317 doi "https://doi.org/10.1200/jco.2014.56.7412" @default.
• W2137602317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25349291" @default.
• W2137602317 hasPublicationYear "2014" @default.
• W2137602317 type Work @default.
• W2137602317 sameAs 2137602317 @default.
• W2137602317 citedByCount "234" @default.
• W2137602317 countsByYear W21376023172014 @default.
• W2137602317 countsByYear W21376023172015 @default.
• W2137602317 countsByYear W21376023172016 @default.
• W2137602317 countsByYear W21376023172017 @default.
• W2137602317 countsByYear W21376023172018 @default.
• W2137602317 countsByYear W21376023172019 @default.
• W2137602317 countsByYear W21376023172020 @default.
• W2137602317 countsByYear W21376023172021 @default.
• W2137602317 countsByYear W21376023172022 @default.
• W2137602317 countsByYear W21376023172023 @default.
• W2137602317 crossrefType "journal-article" @default.
• W2137602317 hasAuthorship W2137602317A5012323508 @default.
• W2137602317 hasAuthorship W2137602317A5024523208 @default.
• W2137602317 hasAuthorship W2137602317A5025135477 @default.
• W2137602317 hasAuthorship W2137602317A5026905234 @default.
• W2137602317 hasAuthorship W2137602317A5029754474 @default.
• W2137602317 hasAuthorship W2137602317A5034705456 @default.
• W2137602317 hasAuthorship W2137602317A5052966036 @default.
• W2137602317 hasAuthorship W2137602317A5055537555 @default.
• W2137602317 hasAuthorship W2137602317A5066993165 @default.
• W2137602317 hasAuthorship W2137602317A5068359755 @default.
• W2137602317 hasAuthorship W2137602317A5071670695 @default.
• W2137602317 hasAuthorship W2137602317A5072938690 @default.
• W2137602317 hasAuthorship W2137602317A5082517668 @default.
• W2137602317 hasAuthorship W2137602317A5089791635 @default.
• W2137602317 hasAuthorship W2137602317A5091812069 @default.
• W2137602317 hasBestOaLocation W21376023171 @default.
• W2137602317 hasConcept C121608353 @default.
• W2137602317 hasConcept C126322002 @default.
• W2137602317 hasConcept C141071460 @default.
• W2137602317 hasConcept C143998085 @default.
• W2137602317 hasConcept C146357865 @default.
• W2137602317 hasConcept C151730666 @default.
• W2137602317 hasConcept C2776256026 @default.
• W2137602317 hasConcept C2776694085 @default.

• next